Cryo-Cell International Inc
NASDAQ:CCEL
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
US |
Cryo-Cell International Inc
NASDAQ:CCEL
|
68.1m USD | -35 306.5 | ||
US |
Cigna Corp
NYSE:CI
|
97.9B USD | 11.8 | ||
US |
C
|
Cigna Group
XMUN:CGN
|
87.3B EUR | 11.5 | |
US |
CVS Health Corp
NYSE:CVS
|
74.6B USD | 15 | ||
DE |
Fresenius SE & Co KGaA
XETRA:FRE
|
16.5B EUR | 8.9 | ||
US |
Laboratory Corporation of America Holdings
NYSE:LH
|
16.4B USD | 28.5 | ||
US |
Quest Diagnostics Inc
NYSE:DGX
|
15.8B USD | 20.2 | ||
US |
DaVita Inc
NYSE:DVA
|
12.9B USD | 23.4 | ||
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.5B EUR | 10.9 | |
DE |
Fresenius Medical Care AG
XMUN:FME
|
11.4B EUR | 10.8 | ||
US |
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | -25.2 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.